UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000028153
Receipt No. R000032222
Scientific Title Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Date of disclosure of the study information 2017/08/15
Last modified on 2019/05/19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Acronym Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Scientific Title Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Scientific Title:Acronym Clinical data over 24 months with dapagliflozin treatment for type 2 diabetes patients in our hospital
Region
Japan

Condition
Condition type2 diabetes
Classification by specialty
Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To explore the effect on glycemic control and the risk of dibetic complications in patients with type 2 diabetes treated with dapagliflozin.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes HbA1c, glycoalbumin
Key secondary outcomes Body weight, Abdominal circumference, blood pressure, liver function, renal function, uric acid, lipid parameters

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Addition of dapagliflozin 5mg
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria 1) Outpatients
2) over 20 years old
3) T2DM
4) eGFR over 30 mL/min/1.73 m2
5) Diet and exercise therapies are well performed
6) Patients who are suspected good-compliant
7) Understanding of the study procedures and agreement to participate in the study, by giving written informed consent
Key exclusion criteria 1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease)
2) Females who are pregnant or who intend to become pregnant within the study
3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV
4) Contraindication with dapagliflozin
5) Patient who disqualified from the study by the investigator for any reason other than given above.
Target sample size 42

Research contact person
Name of lead principal investigator
1st name Yasuhiro
Middle name
Last name Iijima
Organization Tokyo Medical University
Division name Department of Diabetes, Endocrinology and Metabolism
Zip code 160-0023
Address 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo
TEL 03-3342-6111
Email yasuhiro.iijima1203@gmail.com

Public contact
Name of contact person
1st name Yasuhiro
Middle name
Last name Iijima
Organization Manda Memorial Hospital
Division name Diabetes Center
Zip code 060-0062
Address Minami 2, Nishi 1, Chuo-ku, Sapporo
TEL 011-231-4032
Homepage URL
Email yasuhiro.iijima1203@gmail.com

Sponsor
Institute Tokyo Medical University
Institute
Department

Funding Source
Organization none
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Todachuo General Hospital
Address 1-19-3 Honcho, Toda City, Saitama Prefecture
Tel 048-442-1111
Email yasuhiro.iijima1203@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 戸田中央総合病院

Other administrative information
Date of disclosure of the study information
2017 Year 08 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2014 Year 08 Month 19 Day
Date of IRB
Anticipated trial start date
2014 Year 08 Month 19 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 07 Month 10 Day
Last modified on
2019 Year 05 Month 19 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032222

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.